International Reporting Mechanism for Unethical Germline Gene Editing Experiments Is Needed
By G. Owen Schaefer, Markus K. Labude, Yujia Zhu, Roger Sik-Yin Foo, Vicki Xafis,
Trends in Biotechnology
| 11. 04. 2020
The 2018 revelation of the birth of the first babies whose DNA had been edited shocked the world and was met almost instantly with condemnation from scientists, ethicists, and policymakers around the world [1] (Box 1). The news was not a shock to quite everyone, however. A recent article reveals that a large number of individuals around the world knew about the experiment, in one form or another, before the news broke internationally [2]. He Jiankui, who led the experiment, had built up an international network of collaborators for several of his biotechnology ventures and at various stages communicated progress of his experiment to international colleagues. Some now say they tried to discourage him, but none made known the ongoing experiment to the broader international community.
In this article, we argue that revealing such activities is in line with scientists’ responsibilities to uphold the integrity and trustworthiness of the scientific enterprise. However, the international context complicates the situation; it is not clear whom individuals who knew about the experiment should have approached. To fill...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...